SCHEMBL7342007

SCHEMBL7342007

CS(=O)(=O)Oc1ccc2cc(C(=N)N)ccc2c1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FTO Q9C0B1 1/20 0.54
PLAU P00749 11/20 0.51
PLG P00747 7/20 0.51
PRSS1 P07477 7/20 0.51
F2 P00734 7/20 0.51
KLK1 P06870 5/20 0.51
KLKB1 P03952 5/20 0.51
F12 P00748 2/20 0.50
C1R P00736 2/20 0.48
F10 P00742 2/20 0.48
ST14 Q9Y5Y6 2/20 0.48
ALDH1A1 P00352 2/20 0.48
TMPRSS2 O15393 1/20 0.48
MLNR O43193 1/20 0.48
LMNA P02545 1/20 0.48
ITGB3 P05106 1/20 0.48
HPN P05981 1/20 0.48
CHRM2 P08172 1/20 0.48
ITGA2B P08514 1/20 0.48
C1S P09871 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31266874 1.00 FTO (0.54) FTOPLAUPLGPRSS1F2
SCHEMBL7341668 0.87 FTO (0.69) FTOPLAUPLGPRSS1F2
SCHEMBL28716598 0.80 KDM4E (0.64) ALDH1A1
SCHEMBL30525134 0.80 KDM4E (0.64) ALDH1A1
SCHEMBL19478884 0.80 MEN1 (0.61) FTOPLAUPLGPRSS1F2
SCHEMBL10938172 0.79 FTO (0.66) FTOPLAUPLGPRSS1F2
SCHEMBL3368290 0.78 PRSS1 (0.68) PLAUPLGPRSS1F2KLK1
SCHEMBL31546801 0.78 PRSS1 (0.68) PLAUPLGPRSS1F2KLK1
SCHEMBL7333078 0.77 ALDH1A1 (0.46) FTOPLAUPRSS1F2ST14
SCHEMBL30697344 0.77 STS (0.53) PLAUPLGALDH1A1MAPTHGFAC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119504499-A Synthesis method of 6-amidino-2-naphthol mesylate 江苏杜瑞制药有限公司 2025-02-25 CN claimed
CN-119390614-A Preparation method of nafamostat mesylate 河北广祥制药有限公司 2025-02-07 CN claimed
CN-119143634-A Preparation method of nafamostat mesylate 北京诺康达医药科技股份有限公司 2024-12-17 CN claimed
CN-117185963-A Preparation method of high-purity nafamostat mesylate 华仁药业(日照)有限公司 2023-12-08 CN claimed
CN-116479485-B High-reliability lead frame and preparation method thereof 泰州东田电子有限公司 2023-10-20 CN claimed
CN-116479485-A High-reliability lead frame and preparation method thereof 泰州东田电子有限公司 2023-07-25 CN claimed
WO-2022164150-A1 NAFAMOSTAT MESYLATE AND METHOD FOR PRODUCING INTERMEDIATE THEREOF (주)국전약품 2022-08-04 WO claimed
CN-110330447-B Preparation method and application of nafamostat mesylate intermediate 北京赛升药业股份有限公司 2022-04-15 CN claimed
CN-102225903-B Amidino guanido substituted aromatic heterocyclic copmound and synthesis and use thereof REN JIANDONG 2014-11-26 CN claimed
US-4777182-A ENZYME, HORMONE, COMPLEMENT INHIBITORS TORII & CO., LTD. (JP) 1988-10-11 US claimed
CN-121471113-A Nafamostat medium Process for the preparation of intermediates 鲁南制药集团股份有限公司 2026-02-06 CN disclosed
CN-119390614-B Preparation method of nafamostat mesylate 河北广祥制药有限公司 2025-09-19 CN disclosed
US-20250188022-A1 PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 2025-06-12 US disclosed
CN-119504499-A Synthesis method of 6-amidino-2-naphthol mesylate 江苏杜瑞制药有限公司 2025-02-25 CN disclosed
CN-119504499-A Synthesis method of 6-amidino-2-naphthol mesylate 江苏杜瑞制药有限公司 2025-02-25 CN disclosed
US-4563527-A INHIBITORS OF TRYPSIN, PLASMIN, KALLIKREIN, THROMBIN AND COMPLEMENT TORII & CO., LTD. (JP) 1986-01-07 US disclosed
US-4532255-A Amidine compounds and anticomplement agent comprising same TORII & CO., LTD. (JP) 1985-07-30 US disclosed
US-4496584-A ANTITRYPSIN, ANTIKALLIKREIN, ANTITHROMBIN OR ANTIPLASMIN AGENT TORII & CO. LTD. (JP) 1985-01-29 US disclosed
US-4454338-A 6-AMIDINO-2-NATHTHYL-4-GUANIDINOBENZOATE TORII & CO., LTD. (JP) 1984-06-12 US disclosed
EP-0048433-A2 Novel amidine compounds, process for producing same and anti-complement agent comprising them TORII & CO., LTD. (JP) 1982-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250188022-A1 PROCESS FOR THE PREPARATION OF NAFAMOSTAT, CAMOSTAT AND THEIR DERIVATIVES TPMT, ADH1C, ADH1A FTO 558/4885PLAU 374/4885PLG 1075/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.